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Abstract
There is a lack of clear guidance for the prophylactic use of anticoagulants for patients undergoing laparoscopic adjustable gastric
banding (LAGB) surgery.
This study aimed to evaluate the risk of venous thromboembolism (VTE), prophylactic use of enoxaparin and clinical outcomes in
patients undergoing primary and revisional LAGB procedures.
A retrospective study evaluated the prophylactic use of enoxaparin in adult patients who underwent primary and revisional (band
and port) LAGB procedures. The incidence of VTE andmajor bleeding was investigated during a 90-day follow-up period. Descriptive
and inferential statistics were used for data analysis.
We included 112 and 100 patients who had undergone primary and revisional (24 band procedures and 76 port procedures)
LAGB surgery, respectively. The majority of patients (97%) had a mild risk of VTE development using a post-discharge VTE risk
calculator tool published from the Cleveland Clinic. All primary procedure patients received prophylactic enoxaparin, compared to
79% and 20% of revisional patients who underwent band and port procedures, respectively (P< .001). The overall VTE incidence
was 0.9%, with no significant difference between patients who did or did not receive chemoprophylaxis (0.7% and 1.5%,
respectively; P= .58). No major bleeding events were observed.
Chemoprophylaxis may not be required in all patients undergoing low-risk LAGB surgery unless there are additional risk factors,
such as the presence of super-super-morbid obesity or concomitant hormone replacement therapy. More studies are needed on the
prophylactic use and dosing of enoxaparin in patients undergoing LAGB procedures to provide high-level evidence.
Abbreviations: ACS-NSQIP = American College of Surgeons-National Surgical Quality Improvement Programme, ASA =
American Society of Anaesthesiologists, ASMBS = American Society for Metabolic and Bariatric Surgery, BMI = body mass index,
CHEST = American College of Chest Physicians, HRT = hormone replacement therapy, LAGB = laparoscopic adjustable gastric
banding, LMWH = low molecular weight heparin, LOS = length of hospital stay, NICE = National Institute for Health and Care
Excellence, SNIIRM = French National Health Care System, UFH = unfractionated heparin, VTE = venous thromboembolism.
Keywords: dose, enoxaparin, laparoscopic adjustable gastric banding, obese, prophylaxis, surgery
1. Introduction
Bariatric surgery is considered the most effective treatment in the
management of morbid obesity and prevention of obesity-related
complications.[1] The number of obese patients undergoing
bariatric surgery has increased more than 10-fold in the past 2
decades.[2] One of the main reasons for this increase has been the
development of laparoscopic techniques, which offer an excellent
safety profile.[1] However, venous thromboembolism (VTE)
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remains a significant cause of morbidity and mortality during the
post-operative period.[3] The incidence of VTE ranges from 0.2%
to 3.5% in bariatric patients undergoing laparoscopic surgery.[3]
Mechanical prophylaxis methods, such as thromboembolic
deterrent stockings and sequential compression devices, and
chemoprophylaxis, such as unfractionated heparin (UFH) or low
molecular weight heparin (LMWH), are often used to prevent
VTE in patients undergoing bariatric surgery. The routine use of
mechanical prophylaxis is recommended by various guidelines,
such as those of the American Society forMetabolic and Bariatric
Surgery (ASMBS), the American College of Chest Physicians
(CHEST) and the National Institute for Health and Care
Excellence (NICE).[4–6] However, studies have reported incon-
sistent findings regarding the potential need, choice of drug,
dosing regimen, and duration for VTE chemoprophylaxis.
Generally, there is consensus that enoxaparin is more effective
in VTE prevention compared to UFH, without increasing the
bleeding risk in bariatric surgical patients.[7] Yet, controversy
regarding the use and dose of enoxaparin exists in the literature;
recommendations have ranged from its use not being essential
(mechanical prophylaxis alone is enough)[8,9] to the use of high-
dose enoxaparin (60mg twice daily).[10,11] Similarly, some
studies have reported that an extended duration of chemopro-
phylaxis for 10 days or 2 weeks post-discharge resulted in less
VTE complications compared to in-hospital use only.[11–13]
The ASMBS position statement published in 2013 reported
there was no level 1 evidence regarding the type, dose and
duration of chemoprophylaxis to be used in bariatric surgical
patients.[4] The CHEST guidelines published in 2012 recom-
mended the use of LMWH or UFH in bariatric surgical patients
who have moderate (grade 2B) or high (grade 1B) VTE risk;
however, no information regarding the dose and duration of
chemoprophylaxis was provided.[5] The NICE guidelines
published in 2018 suggested the use of chemoprophylaxis
(LMWH or fondaparinux sodium) in all patients with low
bleeding risk, and for it to be continued while the patient had
significantly reduced mobility.[6] Importantly, these guidelines
did not distinguish between types of bariatric procedure (gastric
bypass, sleeve gastrectomy, gastric banding) and surgical
techniques (open vs laparoscopic) in regard to VTE prophylaxis.
In light of this variation and uncertainty, we retrospectively
examined current local practice for chemoprophylaxis in patients
undergoing primary and revisional bariatric surgery (laparo-
scopic adjustable gastric banding; LAGB). We estimated the risk
of VTE in each patient using a post-discharge VTE risk
assessment tool published by the Cleveland Clinic.[14] We
determined the use (dose and duration) of chemoprophylaxis
and the incidence of adverse outcomes (VTE and bleeding
events). Finally, we identified the factors associated with the use
of chemoprophylaxis.
2. Methods
Ethical approval for this study was obtained from the Tasmanian
Health and Human Research Ethics Committee (H0015795).
The need for consent from patients was waived by the committee
due to the retrospective nature of the study and the collection of
non-identifiable patient information.
A retrospective study was conducted of adult (age ≥ 18 years)
obese patients (body mass index (BMI) ≥ 30kg/m2) who
underwent primary and revisional bariatric surgery at the Royal
Hobart Hospital and the Hobart Private Hospital, from January
1, 2013, to December 31, 2017. The sole primary bariatric
procedure at our study sites was LAGB. Revisional procedures
were done for adjustment, replacement, or removal of bands, as
well as adjustment, replacement, or removal of ports. Patientswere
excluded from the study if they were on regular anticoagulant or
vitamin K therapy, underwent a concurrent surgical procedure
(e.g., hysterectomy), or had an established congenital or acquired
bleeding disorder, varicose veins, renal impairment with an
estimated glomerular filtration rate<60mL/min/1.73m2, prior
heparin-induced thrombocytopaenia, haemorrhagic stroke within
the previous3months, other surgerywithin the previous3months,
or if relevant informationwasmissing. Patients hadbeenadvised to
stop taking any non-steroidal anti-inflammatory drugs and aspirin
5 days preoperatively.
A list of patients who had undergone primary and revisional
LAGB during the study period was obtained from hospital coding
databases. Patients’ medical records were reviewed to confirm
eligibility and to collect demographic and clinical information,
including age, gender, body mass index, length of hospital stay,
duration of surgical procedure, American Society of Anaesthesi-
ologists score,[15] return to operating room, incidents of dyspnoea
at rest, smoking status, presence of diabetesmellitus, hypertension,
congestive heart failure, paraplegia, or obstructive sleep apnoea,
history of VTE, oral contraceptive, or hormone replacement
therapy (HRT) use, details of mechanical prophylaxis, use of
prophylactic anticoagulant (including dose and duration), and the
occurrence of VTE (deep vein thrombosis and/or pulmonary
embolism; deep vein thrombosis , and/or pulmonary embolism), or
major bleeding complications within 90 days following the
procedure. Colour Doppler ultrasound and CT pulmonary
angiography techniques were used for diagnosis of VTE at our
study sites. To define major bleeding, we used the criteria of the
International Society on Thrombosis and Haemostasis: fatal
bleeding; bleeding in vital organs (intracranial, intraspinal,
retroperitoneal, intra-articular, pericardial, intraocular); bleeding
at a surgical site requiring reoperation; and bleeding associated
with a reduction in haemoglobin of at least 2g/dL or requiring
transfusion of at least 2 units of packed red cells/whole blood.[16]
Categorical variables were expressed as count (percentage) and
continuous variables as median (range). Fischer exact test and
Pearson X2 test were used for categorical variables to compare
primary and revisional procedures. The Kruskal –Wallis test was
used for continuous variables to compare demographic and
clinical variables and prophylactic anticoagulant usage for
primary and revisional procedures. Univariate logistic regres-
sions were used to identify variables associated with enoxaparin
use. Subsequently, variables with a P-value < .15 in the
univariate analyses, procedure type, and VTE risk were
considered in a multivariate regression analysis.
We also compared outcomes for our primary procedure cohort
with the American College of Surgeons-National Surgical Quality
Improvement Programme (ACS-NSQIP) and the FrenchNational
Health Care System (SNIIRM).[14,17] Only the primary LAGB
procedure cohort was compared because the published data do
not include revisional procedures. The one proportion sample
test was used to compare our incidence of VTE and major
bleeding with these data.
3. Results
Out of 262 screened patients, 212 met the inclusion criteria
(Fig. 1). One hundred twelve underwent primary LAGB and 100
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had revisional (24 band and 76 port) procedures. Socio-
demographic and clinical characteristics of the patients are
presented in Table 1. Patients in both cohorts were predomi-
nantly female. The primary procedure cohort had a significantly
higher mean weight and BMI. Primary and revisional band
procedure patients had longer hospital lengths of stay (median of
1 day vs 0 days, P< .001) compared to the port procedure
patients. Almost all patients in the primary (95%), revisional
band (100%) and revisional port procedures (99%) categories
had mild risk of VTE.[14]
Mechanical prophylaxis was used during hospital stay in
100% of patients undergoing primary procedures compared to
96% and 84% for revisional band and port procedures,
respectively. All patients in the primary procedure cohort were
given the combination of thromboembolic deterrent, sequential
compression devices and enoxaparin, compared to 75% in the
revisional band procedures and just 18% of patients in the
revisional port procedures cohorts (P<0.001). Overall, 69% of
patients received chemoprophylaxis. The use of prophylactic
enoxaparin was significantly higher in the primary and revisional
band procedure cohorts compared to the revisional port
Patients screened (2013-2017)
(n=262)
Excluded Patients (n=50)
 Admission anti-coagulant/Vitamin K. (n=10)
 eGFR < 60 ml/min/1.732 (n=7)
 Missing data (n=4)
 Age < 18 years (n=2)
 Varicose vein (n=2)
 Recent surgery < 3months (n=5)
 Non-Obese (n=17)
 Heparin induced thrombocytopenia/Congenital
bleeding disorder (n=3)
Patients included (2013-2017)
(n=212)
Figure 1. Flow diagram of patient inclusion.
Table 1
Socio-demographic and clinical variables (N=212).
Revisional procedures (n=100)
Variable Primary Procedures (n=112) Band Procedures (n=24) Port Procedures (n=76) P-value
Gender .003
Female, n (%) 86 (76.8) 16 (66.7) 70 (92.1)
Age (yr), median (range) 47.0 (18.0–69.0) 49.5 (25.0–71.0) 46.0 (24.0–67.0)
Weight (kg), median (range) 135.5 (87.0–210.0) 112.0 (88.0–178.0) 120.0 (79.0–181.0) <.001
BMI (kg/m2), median (range) 48.9 (36.2–75.3) 38.6 (34.5–62.5) 45.0 (32.4–64.9) <.001
TED/SCD
Yes, n (%) 112 (100.0) 23 (96.0) 64 (84.2) <.001
Length of hospital stay, n (%) <.001
Day procedure only 0 (0.0) 7 (29.7) 62 (81.6)
1 day 103 (92.0) 10 (41.7) 11 (14.5)
2 days 6 (5.4) 5 (20.8) 1 (1.3)
3 days 3 (2.7) 0 (0.0) 2 (2.6)
4 days 0 (0.0) 2 (8.3) 0 (0.0)
Days, median (range) 1 (1–3) 1 (0–4) 0 (0–3)
Duration of surgery (min), median (range) 48.5 (30.0–113.0) 64.0 (25.0–145.0) 45.0 (20.0–92.0) <.001
ASA score
1, n (%) 0 (0.0) 1 (4.2) 1 (1.3)
2, n (%) 36 (32.1) 9 (37.5) 22 (28.9)
3, n (%) 76 (67.9) 13 (54.2) 53 (69.7)
4, n (%) 0 (0.0) 1 (4.2) 0 (0.0)
Congestive heart failure
Yes, n (%) 2 (1.8) 1 (4.2) 0 (0.0)
Paraplegia
Yes, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Return to operating room
Yes, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Dyspnoea at rest
Yes, n (%) 6 (5.4) 1 (4.2) 0 (0.0)
Smoker
Yes, n (%) 26 (23.2) 7 (29.2) 19 (25.0)
Diabetes mellitus .004
Yes, n (%) 43 (38.4) 9 (37.5) 13 (17.1)
Hypertension
Yes, n (%) 50 (44.6) 7 (29.2) 22 (29.0)
VTE history
Yes, n (%) 3 (2.7) 1 (4.2) 0 (0.0)
Obstructive sleep apnoea
Yes, n (%) 32 (28.6) 4 (16.7) 18 (23.7)
Oral contraceptive/hormone replacement therapy
Yes, n (%) 7 (6.2) 1 (4.2) 2 (2.6)
VTE risk
Mild, n (%) 107 (95.5) 24 (100.0) 75 (98.7)
Moderate, n (%) 4 (3.6) 0 (0.0) 1 (1.3)
High, n (%) 1 (0.9) 0 (0.0) 0 (0.0)
Only statistically significant values (P< .05) are shown under the P-value column.
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procedure cohort (100% and 79%, vs 20%; P< .001). The
majority of patients in the primary and revisional (band and port)
cohorts received 40mg enoxaparin once daily (Table 2). All
patients in the primary procedure cohort received prophylactic
enoxaparin post-discharge, typically for 10 days, compared to
54% of revisional band procedure and just 5% of revisional port
procedure patients. The multivariate logistic regression model
showed that patients who stayed longer in hospital (typically
those who had undergone primary LAGB and band procedures)
were more likely to receive chemoprophylaxis (Table 3); that is,
enoxaparin use was higher in patients who had an overnight stay
in hospital.
Table 2
Thromboprophylaxis practices and outcomes (N=212).
Revisional procedures (n=100)
Regimen
Primary procedures
(n=112)
Band adjustment/ replacement/
removal (n=24)
Port adjustment/ replacement/
removal (n=76) P-value
TED/SCD only, n (%) 0 (0.0) 5 (20.8) 50 (65.8) <.001
Enoxaparin only, n (%) 0 (0.0) 1 (4.2) 1 (1.3)
TED/SCD and Enoxaparin, n (%) 112 (100.0) 18 (75.0) 14 (18.4)
None, n (%) 0 (0.0) 0 (0.0) 11 (14.5)
Peri-operative anticoagulant <.001
Enoxaparin 40mg daily, n (%) 111 (99.1) 17 (70.8) 7 (9.2)
Enoxaparin 60mg daily, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Enoxaparin 80mg daily, n (%) 1 (0.9) 0 (0.0) 1 (1.3)
None, n (%) 0 (0.0) 7 (29.2) 68 (89.5)
Post-operative anticoagulant <.001
Enoxaparin 40mg daily, n (%) 110 (98.2) 16 (66.7) 11 (14.5)
Enoxaparin 60mg daily, n (%) 1 (0.9) 0 (0.0) 0 (0.0)
Enoxaparin 80mg daily, n (%) 1 (0.9) 0 (0.0) 0 (0.0)
None, n (%) 0 (0.0) 8 (33.3) 65 (85.5)
Duration of chemoprophylaxis <.001
Peri-op only, n (%) 0 (0.0) 3 (12.5) 4 (5.3)
Peri-op until discharge, n (%) 0 (0.0) 1 (4.2) 0 (0.0)
Post-op until discharge, n (%) 0 (0.0) 2 (8.3) 7 (9.2)
10 d post-discharge, n (%) 110 (98.2) 13 (54.2) 4 (5.3)
30 d post-discharge, n (%) 2 (1.8) 0 (0.0) 0 (0.0)
None, n (%) 0 (0.0) 5 (20.8) 61 (80.3)
Enoxaparin use
∗
<.001
Yes, n (%) 112 (100) 19 (79.2) 15 (19.7)
VTE within 90-d, n (%) 1 (0.9) 0 (0.0) 1 (1.0) 1.000
Major bleed within 90 d, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Statistically significant values (P< .05) are shown in italics under the P-value column to highlight such significance.
∗
Any of the following regimen of enoxaparin: start at induction until discharge, start post-operatively until discharge, start at induction until post-discharge, or start post-operatively until post-discharge.
Table 3
Logistic regression for variables associated with enoxaparin use (n=212).
Variable Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Gender
Female 0.49 (0.21–1.13) .09 2.09 (0.32–13.64) .44
Age 0.99 (0.96–1.02) .86 —————— ————
Procedure
Primary 0.00 (0.00–0.00) .99 0.00 (0.00–0.00) .99
Duration of surgery (mi) 1.03 (1.01–1.06) .001 1.02 (0.99–1.06) .15
BMI 1.08 (1.04–1.12) <.001 1.03 (0.94–1.12) .45
Overnight stay
∗
Day procedure 307.78 (86.92–1089.87) <.001 33.32 (7.99–130.00) <.001
ASA score
1 1.91 (0.11–32.00) .65 ———— ————
Smoker
Yes 1.15 (0.58–2.92) .68 ———— ————
VTE risk
Mild 1.84 (0.20–16.82) .59 0.00 (0.00–0.00) .99
ASA=American Society of Anesthesiologist, BMI=body mass index, CI= confidence interval, OR= odds ratio.
Variables with P-value less than .15 and other factors which were associated with anticoagulant use (procedure type and VTE risk) were considered in multivariate regression analysis.
VTE risk is categorised into mild and moderate/severe.
∗
Overnight stay is categorized into ≥ 1 d or day procedure (0 d).
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There was 1 VTE occurrence in each of the primary and
revisional port procedure cohorts. Both patients were taking
HRT. One patient (210kg; BMI 75.3kg/m2) who underwent
primary LAGB was diagnosed with a deep vein thrombosis 35
days post-operatively. This patient had received 40mg enox-
aparin at induction and 40mg enoxaparin daily for 10 days post-
discharge. The other patient (118kg; BMI 49.1kg/m2) had
undergone a port adjustment and was diagnosed with pulmonary
embolism 2 months post-operatively, after reporting 4 weeks of
shortness of breath. This patient had received only mechanical
prophylaxis during hospital stay and no chemoprophylaxis. Two
other primary procedure patients developed possible clinical
manifestations of VTE (pain and calf swelling). These patients
underwent diagnostic procedures (colour Doppler ultrasound
and CT pulmonary angiography) but no VTE was detected in
either patient. There was no significant difference in the overall
occurrence of VTE between the primary and revisional procedure
cohorts (0.9% vs 1.0% respectively; P-value=1.00). No major
bleeding event was observed in either cohort. Similarly, there was
no statistically significant difference in the overall 90-day VTE
incidence between the cohorts who received and did not receive
chemoprophylaxis (0.7% vs 1.5%, respectively; P-value= .58).
The majority of clinical and demographic variables in our
primary procedure cohort were similar to those reported in the
American College of Surgeons-National Surgical Quality Im-
provement Programme (ACS-NSQIP) and SNIIRM databases.
The reported incidences of VTE in primary LAGB patients in the
ACS-NSQIP (30 days) and the SNIIRM databases (90 days) were
0.1% (26/24,650) and 0.2% (31/14,947), respectively.[14,17] Our
study’s 30-day and 90-day VTE incidences were not significantly
different compared to the ACS-NSQIP database (0.0% vs 0.1%,
P-value= .63, 95% CI=0.00–3.24) and the SNIIRM database
(0.9% vs 0.2%, P-value= .09, 95%CI=0.02–4.89), respectively.
4. Discussion
We observed low incidences of VTE and no major bleeds in both
primary and revisional LAGB procedures. Surgical procedures
performed laparoscopically are less likely to result in post-
operative VTE compared to open procedures.[18] However,
guidelines such as those of ASMBS, CHEST and NICE do not
recommend specific VTE prophylaxis for LAGB. These guidelines
suggest the same prophylactic chemoprophylactic approach
based on the individual patient risk assessment (VTE vs bleeding
risk) and clinical judgment of the surgeon for all bariatric
procedures regardless of type (gastric banding, gastric bypass,
and sleeve gastrectomy) or technique (laparoscopic or open).[4,6]
Despite the mild risk of VTE development, all of our primary
LAGB procedure patients received chemoprophylaxis.
LAGB is considered the safest bariatric procedure in terms of
VTE risk.[19] According to the ACS-NSQIP database, the 30-day
prevalence of VTE following LAGBwas 0.1% compared to 0.6%
and 0.4% in laparoscopic sleeve gastrectomy and laparoscopic
gastric reduction patients, respectively.[14] Similarly, according to
the SNIIRMdatabase, the reported incidence of 90-day VTEwith
LAGB was lower (0.2%) compared to laparoscopic sleeve
gastrectomy (0.5%) and laparoscopic gastric reduction
(0.6%).[17] A German nationwide survey reported a gradually
declining trend of chemoprophylaxis in LAGB surgery from 2005
(100%) till 2010 (95%), due to shorter length of hospital stay
and less complicated procedures.[20]
A total of 97% of patients who had mild risk of VTE
development received chemoprophylaxis. Yet, studies of laparo-
scopic bariatric surgery have reported that mechanical prophy-
laxis alone provides sufficient VTE prophylaxis if the operation
time is short and the patient becomes ambulatory soon after
surgery.[8,9] Our patients fulfilled both of these criteria; the mean
operation time was shorter (mean=49.7minutes) compared to
sleeve gastrectomy (100minutes) and gastric bypass (135
minutes) patients reported in the ACS-NSQIP database,[14] and
the majority of our patients were ambulatory on the day of
surgery, likely due to the less complex surgical procedure.
A 10-year longitudinal study reported that LAGB resulted in a
higher surgical revision rate compared to gastric bypass and
sleeve gastrectomy.[21] This is a possible explanation for the
relatively high number of revisional procedures in our study,
because LAGB has been the principal bariatric procedure
conducted at our study site since the late 1990s. The mean
duration from primary to revisional procedures was 7.36 years in
our study patients.
This study had some limitations. First, the retrospective study
design meant that we had to rely on the notes available in digital
medical records, and verbal advice from the principal bariatric
surgeon. Secondly, our sample size was relatively small, with
limited statistical power when examining relatively rare out-
comes. Thirdly, we did not screen all patients for VTE after their
surgery, so the incidence may have been under-reported. Lastly,
LAGB is now not a first-choice bariatric procedure in many
countries, including USA, but this is still widely employed in other
countries.
5. Conclusion
A low incidence of VTE was observed in the LAGB surgical cases
in this study, which included a heterogenous mix of primary and
revisional surgeries, with varying use, dose, and duration of
enoxaparin. Because of the low VTE risk associated with LAGB,
chemoprophylaxis may not be required in all patients unless
there are additional risk factors, such as super-super-morbid
obesity (BMI>60kg/m2) or concomitant HRT. As there is no
procedure- and technique-specific thromboprophylaxis advice
for bariatric surgery, surgeons should follow current recom-
mendations, modifying them as required to suit individual
patients’ risk. Further research to provide procedure- and
technique-specific thromboprophylaxis evidence may improve
outcomes.
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